Pharma BD Deal Intelligence
Lilly's $2.4 billion Orna buy staked an early claim in in vivo CAR-T with ORN-252 for B-cell autoimmune disease, but it was quickly overshadowed as the 'foundational entry point' for Lilly's much larger $7 billion Kelonia deal.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Lilly bets on circular RNA for next-generation in vivo cell therapy. The Orna deal, paired weeks later with the up-to-$7B Kelonia acquisition, signals Lilly is…
Eli Lilly to buy Watertown biotech Orna Therapeutics, maker of in vivo CAR-T. The $2.4B deal with milestones marks Lilly's formal entry into the in vivo cell…
After Lilly's $7B Kelonia deal, are there any in vivo CAR-T biotechs left to buy? Lilly has now stitched together Orna's circular RNA payload with Kelonia's…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Eli Lilly agreed to acquire Watertown, MA-based Orna Therapeutics for up to $2.4 billion in cash, comprising an upfront payment plus contingent clinical development milestone payments. The deal adds Orna's engineered circular RNA (oRNA) platform and lead asset ORN-252, a clinical-trial-ready in vivo CD19 CAR-T for B cell-driven autoimmune diseases. The transaction positions Lilly in the emerging in vivo CAR-T arena as an off-the-shelf alternative to ex vivo cell therapy manufacturing.
204K US cases/yr · $2.4B US SLE treatment market 2024 (analyst estimate, third-party)
B cell-driven autoimmune diseases are a family of conditions including systemic lupus erythematosus (SLE), lupus nephritis, myositis, systemic sclerosis, and multiple sclerosis, in which autoreactive B cells drive pathology through autoantibody production, antigen presentation, and cytokine secretion. SLE alone affects an estimated 204,000 people in the US per CDC National Lupus Registries meta-analysis, predominantly women of African American, Hispanic, and Asian descent. Deep B cell depletion via CD19-directed CAR-T has produced drug-free remissions in academic case series, validating B cell reset as a therapeutic concept and spawning a competitive race to industrialize the modality without ex vivo cell manufacturing.
The B cell-driven autoimmune CAR-T competitive landscape splits into three mechanistic camps. Ex vivo autologous CD19 CAR-T is led by Kyverna Therapeutics' KYV-101 (Phase 2/pivotal in SLE, lupus nephritis, myositis, MS, stiff person syndrome; BLA targeted 1H 2026) and Cabaletta Bio's rese-cel (CABA-201) with FDA Fast Track/RMAT in SLE, systemic sclerosis, myositis and MS. Allogeneic CAR-T is represented by Allogene's ALLO-329 and Caribou Biosciences' CB-010 for autoimmune indications. In vivo CAR-T, the camp Lilly is entering via Orna's ORN-252, includes Capstan Therapeutics (acquired by AbbVie, in vivo CD19 CAR-T with LNP-delivered mRNA), Umoja Biopharma (in vivo VivoVec viral vector CAR-T), and AbelZeta's C-CAR168 with positive Phase 1 SLE data at 6 months. Lilly's February 2026 follow-on Kelonia Therapeutics acquisition (up to $7B) doubled down on the in vivo thesis with a complementary lentiviral gene-delivery platform.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Orna Therapeutics, Inc. (this deal) | 2026 | $2.4B | — |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2026 deals · Eli Lilly and Company deals · Immunology deals